FM
PCRX icon

Foster & Motley’s Pacira BioSciences PCRX Stock Holding History

Foster & Motley’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.29M Buy
57,000
+15,943
+39% +$354K 0.07% 206
2025
Q4 		$1.06M Buy
41,057
+25,984
+172% +$618K 0.06% 221
2025
Q3 		$388K Buy
+15,073
New +$370K 0.02% 319

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Foster & Motley's PCRX Position: Q1 2026 in Review

Foster & Motley increased its Pacira BioSciences (PCRX) stake by 39% in Q1 2026, buying an estimated $354K and bringing the position to 57,000 shares worth $1.29M. The position accounts for 0.07% of the portfolio, ranked #206.

Foster & Motley first reported a position in PCRX in Q3 2025 and has held it in 3 quarters since. 241 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.

  • Foster & Motley held 57,000 shares of Pacira BioSciences worth $1.29M as of Q1 2026.
  • Foster & Motley bought 15,943 Pacira BioSciences shares in Q1 2026, an estimated $354K.
  • Pacira BioSciences made up 0.07% of Foster & Motley's portfolio in Q1 2026, its #206 holding.
  • Foster & Motley first reported a position in Pacira BioSciences in Q3 2025 and has held it in 3 quarters since.
  • 241 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.

Based on Foster & Motley's 13F filing for Q1 2026, filed 21 Apr 2026.